bluebird bio Beheer

Beheer criteriumcontroles 2/4

De CEO bluebird bio is Andrew Obenshain, benoemd in Jan2021, heeft een ambtstermijn van 3.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.05M, bestaande uit 22.4% salaris en 77.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.048% van de aandelen van het bedrijf, ter waarde $ 34.72K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 13.7 jaar.

Belangrijke informatie

Andrew Obenshain

Algemeen directeur

US$3.0m

Totale compensatie

Percentage CEO-salaris	22.4%
Dienstverband CEO	3.8yrs
Eigendom CEO	0.05%
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	13.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Andrew Obenshain's beloning veranderd ten opzichte van bluebird bio's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$293m
Jun 30 2024	n/a	n/a	-US$319m
Mar 31 2024	n/a	n/a	-US$301m
Dec 31 2023	US$3m	US$682k	-US$212m
Sep 30 2023	n/a	n/a	-US$63m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$89m
Dec 31 2022	US$2m	US$643k	-US$230m
Sep 30 2022	n/a	n/a	-US$431m
Jun 30 2022	n/a	n/a	-US$507m
Mar 31 2022	n/a	n/a	-US$563m
Dec 31 2021	US$9m	US$486k	-US$563m

Compensatie versus markt: De totale vergoeding ($USD 3.05M ) Andrew } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 353.74K ).

Compensatie versus inkomsten: De vergoeding van Andrew is gestegen terwijl het bedrijf verliesgevend is.

CEO

Andrew Obenshain (50 yo)

3.8yrs

Tenure

US$3,049,181

Compensatie

Mr. Andrew Obenshain has been the Chief Executive Officer and Director of bluebird bio, Inc. since 2021 and serves as its President. He served as President of Severe Genetic Diseases since October 2020 unt...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Andrew Obenshain	President	3.8yrs	US$3.05m	0.048% $ 34.7k
Thomas Klima	Chief Commercial Officer & COO	2.3yrs	US$1.33m	0.087% $ 62.9k
Richard Colvin	Chief Medical Officer	3.7yrs	US$1.34m	0.022% $ 16.1k
Oliver Sterling	CFO & Principal Accounting Officer	less than a year	geen gegevens	geen gegevens
Joseph Vittiglio	Chief Legal & Business Officer and Secretary	1.8yrs	geen gegevens	0.0037% $ 2.7k
Jess Rowlands	Head of Corporate Communications	1.9yrs	geen gegevens	geen gegevens
Andrea Walton	Chief People Officer	2.8yrs	geen gegevens	geen gegevens
Kasra Kasraian	Senior Vice President of Technical Development & Operations	no data	geen gegevens	geen gegevens
Scott Shoemaker	Senior Vice President of Quality	3.8yrs	geen gegevens	geen gegevens
Sarah Alspach	Senior Vice President of External Affairs	1.9yrs	geen gegevens	geen gegevens
Leslie Wilder	VP & Head of Regulatory Science	no data	geen gegevens	geen gegevens
Jessica Whitten	VP & Global Controller	no data	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0HOH wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Andrew Obenshain	President	3.8yrs	US$3.05m	0.048% $ 34.7k
Philip Reilly	Member of Scientific Advisory Board	13.7yrs	geen gegevens	geen gegevens
Philippe Leboulch	Co-Chair of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Stephen Goff	Member of Scientific Advisory Board	13.7yrs	geen gegevens	geen gegevens
Mark Vachon	Independent Chairman	10.3yrs	US$200.91k	0.013% $ 9.3k
Mitchell Finer	Member of Scientific Advisory Board	9.3yrs	US$1.57m	geen gegevens
Malcolm Brenner	Member of Scientific Advisory Board	13.7yrs	geen gegevens	geen gegevens
Christof von Kalle	Member of Scientific Advisory Board	13.7yrs	geen gegevens	geen gegevens
John Agwunobi	Independent Director	7.4yrs	US$160.91k	0.014% $ 9.8k
Nick Leschly	Director	14.7yrs	US$96.41k	0.23% $ 168.4k
R. Humphries	Member of Scientific Advisory Board	13.7yrs	geen gegevens	geen gegevens
Elisabeth Leiderman	Independent Director	3yrs	US$167.91k	0.011% $ 8.2k

13.7yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0HOH zijn ervaren en ervaren (gemiddelde ambtstermijn van 13.7 jaar).

bluebird bio Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

President recently sold US$60k worth of stock

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

Less than half of directors are independent

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

Recent updates

Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.66 loss in 3Q 2023)

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Now 41% undervalued after recent price drop

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Revenue and earnings growth

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.94 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Now 20% undervalued after recent price drop

New minor risk - Insider selling

President recently sold US$60k worth of stock

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$1.36 loss in 2Q 2022)

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

First quarter 2023 earnings released: EPS: US$0.21 (vs US$1.66 loss in 1Q 2022)

Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021)

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.94 loss per share (vs US$2.23 loss in 3Q 2021)

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

Treasurer recently sold US$78k worth of stock

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

President recently sold US$96k worth of stock

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021)

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Less than half of directors are independent

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

Bluebird Bio, Inc. Announces Executive Changes

bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer

CEO & Director recently sold US$74k worth of stock

bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. to Launch Both beti-cel and eli-cel for Patients in the U.S. in Mid-2022

bluebird bio, Inc. Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program

bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor

bluebird bio, Inc. Announces Updated Results from its Phase 1/2 HGB-206 Study of Lovotibeglogene Autotemcel Gene Therapy

New Data At ASH21, Published in Nejm Further Demonstrate Beti-Cel as A Potentially Curative One-Time Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Ti and Normal or Near-Normal Adult Hb Levels

Independent Director Wendy Dixon has left the company

Bluebird Bio, Inc. Announces FDA Priority Review of Biologics License Application for Beti-Cel Gene Therapy for Patients with ß-Thalassemia Who Require Regular Red Blood Cell Transfusions

Third quarter 2021 earnings released: US$3.16 loss per share (vs US$2.94 loss in 3Q 2020)

bluebird bio, Inc. Submits Biologics License Application to FDA for Betibeglogene Autotemcel (beti-cel) Gene Therapy for Patients with ß-Thalassemia Who Require Regular Red Blood Cell Transfusions

bluebird bio, Inc. announced that it expects to receive $74.977264 million in funding from Baker Bros. Advisors LP

Second quarter 2021 earnings released: US$3.58 loss per share (vs US$0.35 loss in 2Q 2020)